Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceLongevity & antioxidants

MitoQ (Mitoquinol Mesylate)

A CoQ10 derivative engineered to accumulate inside mitochondria. Small trials from one research group show improved blood vessel function in older adults; broader anti-ageing and energy claims are not supported.

Evidence last reviewed: August 2026

What the science says

  • Vascular function in older adults Limited evidence

    A randomized crossover trial in healthy older adults found six weeks of 20 mg/day MitoQ improved brachial artery flow-mediated dilation and reduced aortic stiffness compared with placebo. The sample was small, and a later acute-dosing study showed the response depends heavily on baseline fitness and vessel function.

  • Safety at high acute doses Limited evidence

    A randomized crossover trial found a single high dose of MitoQ did not raise urinary markers of kidney injury in healthy adults. This addresses one safety question and says nothing about efficacy or long-term use.

  • Energy, ageing and neurodegeneration Limited evidence

    MitoQ has been trialled in Parkinson's disease and hepatitis C without clear clinical benefit, and no trial supports the general claims about energy or slowed ageing. The mitochondrial-targeting chemistry is well established; the outcomes are not.

Dosage & safety

Studied doseHuman trials generally used 10–20 mg/day of mitoquinol mesylate, taken in the morning on an empty stomach. Higher doses have not shown greater benefit.
SafetyGenerally well tolerated at 10–20 mg/day; gastrointestinal upset is the most common complaint and higher doses can cause nausea. Long-term safety is unknown, and as with any potent antioxidant there is a theoretical concern about blunting exercise adaptations. Not studied in pregnancy, breastfeeding or children.

Scientific references

Where to buy

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Longevity & antioxidants